Senzar Asset Management Llc Upped Its Exact Sciences Corp (Put) (NASDAQ:EXAS) Position as Price Declined by $21.45 Million

May 17, 2018 - By Matthew Richard

Exact Sciences Corporation (NASDAQ:EXAS) Corporate LogoBig Money Sentiment decreased to 0.88 in Q4 2017. It has change of 0.13, from 2017Q3’s 1.01. The ratio worsened due to EXAS positioning: 25 sold and 105 reduced. 44 funds bought holdings and 70 increased holdings. Investors holded 93.65 million in 2017Q3 but now own 92.48 million shares or 1.24% less. Massachusetts Financial Service Ma has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Financial Bank Of Montreal Can holds 0% or 31,254 shs. Credit Agricole S A holds 20,000 shs or 0.07% of its capital. Los Angeles And Equity Inc has invested 0.02% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Metropolitan Life Insur Communication owns 36,687 shs or 0.03% of their US capital. Green Valley Invsts Ltd Llc invested in 2.31% or 923,704 shs. Natl Bank Of America De reported 1.57M shs. Eam Invsts Ltd Liability Co invested in 0.34% or 49,125 shs. Envestnet Asset Mgmt Inc reported 2,725 shs. Alps Inc has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Proshare Advsr Ltd Llc has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Tudor Et Al holds 5,357 shs. Jane Street Grp Incorporated invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). 1.75M are owned by Cap. State Street Corp invested in 3.53M shs or 0.01% of the stock.

EXAS registered $25.11 million net activity with 0 insider buys and 21 insider sales since January 2, 2018. On Thursday, May 10 Shares for $381,447 were sold by WYZGA MICHAEL S. COWARD D SCOTT sold $141,341 worth of Exact Sciences Corporation (NASDAQ:EXAS) or 2,708 shs on Friday, March 9. $276,367 worth of stock was sold by ARORA MANEESH on Friday, March 9. Zanotti Katherine S sold $325,440 worth of stock or 7,232 shs. The insider Doyle James Edward sold 3,098 shs worth $126,925. $756,271 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by LIDGARD GRAHAM PETER.

The stake In Exact Sciences Corp (Put) (NASDAQ:EXAS) held by Senzar Asset Management Llc was increased. According to 2018Q1 Securities and Exchange regulatory form the increase is 9679.82%. 536,359 shares were bought by Senzar Asset Management Llc as Exact Sciences Corp (Put) (NASDAQ:EXAS) stock declined 19.82% with the market. It held 541,900 shares of Exact Sciences Corp (Put) (NASDAQ:EXAS) at the end of 2018Q1, valued at $21.86 million, up from 5,541 last quarter. $6.21B is the Exact Sciences Corp (Put)’s market cap. EXAS is hitting $50.96 during the last trading session, after increased 0.37%.Exact Sciences Corporation has volume of 1.04 million shares. Since May 17, 2017 EXAS has risen 81.43% and is uptrending. EXAS outperformed by 69.88% the S&P 500.

Senzar Asset Management Llc manages about $442.00 million and $316.94 million US longs. Its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) was decreased by 207,732 shares to 70,668 shares valued at $3.83M in 2018Q1, according to the regulatory form. It decreased Cvs Health Corp (NYSE:CVS) position by 194,670 shares to 120,830 shares, and cut its Tg Therapeutics Inc (NASDAQ:TGTX) stake.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

A total of 11 analysts rate Exact Sciences (NASDAQ:EXAS) as follows: 8 “Buy”, 3 “Hold” and 0 “Sell”. Тherefore 73% are bullish. (NASDAQ:EXAS) has 16 ratings reports on 17 May 2018 according to StockzIntelligence. On Wednesday, December 20 the firm earned “Buy” rating by Cowen & Co. The company rating was maintained by Benchmark on Wednesday, January 17. The stock rating was maintained by William Blair with “Buy” on Thursday, March 29. On Wednesday, March 28 the firm has “Buy” rating given by Leerink Swann. On Tuesday, March 27 the company was maintained by Jefferies. On Friday, February 23 Benchmark downgraded Exact Sciences Corporation (NASDAQ:EXAS) to “Hold” rating. On Friday, February 23 the company was maintained by Stephens. On Thursday, January 18 Craig Hallum maintained the shares of EXAS in report with “Buy” rating. On Friday, February 23 the stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Canaccord Genuity. On Monday, March 19 the stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given by Canaccord Genuity.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.The firm is valued at $6.21 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer.Currently it has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: